Moon Jeong Lee, MD, Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland, was honored as the recipient of the inaugural Visionary in Eye Care Resident Recognition Award for the category of Best in Ophthalmology during the EyeCon 2023 conference, December 1-2, at the Marriott Sanibel Harbour Resort and Spa in Sanibel, Florida.
Marta Stevanovic, MD, Massachusetts Eye and Ear, Harvard Medical School, Boston, was honored as the recipient of the inaugural Visionary in Eye Care Resident Recognition Award for the category of Best in Retina during the EyeCon 2023 conference, December 1-2, at the Marriott Sanibel Harbour Resort and Spa in Sanibel, Florida.
Analisa Arosemena, MD, underscores the importance of year-round glaucoma control through extended-release medications and laser treatments at EyeCon 2023.
Oluwatosin U. Smith, MD, and Peter J. McDonnell, MD, discuss their experience at EyeCon 2023, highlighting the latest updates in retina, cataract and refractive surgery, and the growing epidemic of myopia worldwide.
Jennifer Loh, MD, discusses the significance of maintaining a healthy ocular surface before surgery and exploring collaborative approaches for improved patient comanagement between ophthalmologists and optometrists at EyeCon 2023.
Benjamin Y Xu, MD, spoke with the Ophthalmology Times team about the real-world safety analysis of patients treated with intracanalicular dexamethasone insert using IRIS Registry at this year's American Academy of Ophthalmology meeting.
Rupa Wong, MD, spoke with the Ophthalmology Times team about Luminopia, the first FDA-approved digital therapeutic for amblyopia at this year's American Academy of Ophthalmology meeting.
Korean researchers reported Ptosis was associated with COVID-19 vaccination, while Guillain-Barré syndrome/Miller Fisher syndrome was associated with the COVID-19 infection.
Moving toward eliminating drug and chemical safety testing in animals.
The company announced a resubmission of the ONS-5010 BLA on track for the end of calendar year 2024, pending final agreement on a clinical trial protocol with the FDA and successful completion of the required additional clinical trial.
According to the company, its Zilia Ocular FC system is designed for assessing ocular biomarkers.
Earlier this year, Harrow acquired the US commercial rights to Triesence. Aside from the transfer of the Triesence NDA ahead of the date previously agreed to, all other acquisition terms remain unchanged.
The Phase 2 study is evaluating the efficacy and safety using 2 concentrations of SBI-100 OE vs. placebo, dosing twice a day for 14 days.
The augmented reality headset compensates for central vision loss to enhance the visual clarity of patients with age-related macular degeneration and other conditions such as Stargardt disease.
According to the company, an additional trial is required to show positive effects on the treatment of ocular symptoms in dry eye disease.
By joining the group of physicians, researchers, and industry partners working together to define optimal biomarkers and endpoints in AMD, RetinAI hopes to forge a global retinal imaging initiative targeting research in the disease.
Medicare Administrative Contractors (MACs) that issued the new LCDs have all corrected errors in criteria for coverage of CPC resulting in significantly broader patient qualification in the jurisdictions of these MACs.
Physician details her journey from sustaining career-ending injury to insurance advocate.
CorNeat Vision is among the many companies working to try to maintain operations amid the conflict.
Eyecare providers report slower Q3 and increased concern for the US economy and inflation rates.
Orbis advances cataract surgery training in low-resource areas with technology
Flinders University Ophthalmologists have devised a novel glaucoma polygenic risk score (PRS) that identifies those at high risk of losing their sight and prioritizes their treatment.
A study of the course was conducted in Vietnam, and showed participant scores doubled following the online course, to a level like local ophthalmologists.
Mohammed Genead, MD, CEO of Aviceda spoke with the Ophthalmology Times team about the company's Phase II/III SIGLEC trial part 1 results, which were shared at this year's American Academy of Ophthalmology meeting.
Rob Thornhill, CEO of Centricity Vision spoke with the Ophthalmology Times team about the company's newest developments at this year's American Academy of Ophthalmology meeting.
The Kingfisher Study found that the visual outcomes after 1 year of brolucizumab, 6 mg, (Beovu, Novartis) in participants with diabetic macular edema (DME) did not differ significantly from those obtained with aflibercept
Marco A. Zarbin, MD, spoke with the Ophthalmology Times team about conducting a post-hoc analysis of the YOSEMITE and RHINE clinical trials and presenting the results at this year's American Academy of Ophthalmology meeting.
Slit lamp evaluation can provide valuable information for treatment course.
The aim of the MBCT was possibly re-training patient brains to remove their static-type images.
